BRCA1 and ovarian cancer: In Japan, though comprehensive genomic profiling can be conducted to test for somatic BRCA1/2 mutations, its wide application in clinical practice is hampered by its high cost and the reservation of testing in patients with primary ovarian cancer who cannot be treated with standard therapy.